Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
Lei Zhang1† 
Zhi-Ping Yan2,3,4† 
Zhong-Heng Hou1† Peng Huang1† Min-Jie Yang2,3,4 Shuai Zhang1 Shen Zhang1 Shao-Hua Zhang5 
Xiao-Li Zhu1‡ 
Cai-Fang Ni1‡ 
Qiang Li6*‡- 1Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China
- 2Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China
- 3Shanghai Institution of Medical Imaging, Shanghai, China
- 4National Clinical Research Center for Interventional Medicine, Shanghai, China
- 5Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen, China
- 6Department of Radiology, The Affiliated People’s Hospital of Ningbo University, Ningbo, China
by Zhang, L., Yan, Z.-P., Hou, Z.-H., Huang, P., Yang, M.-J., Zhang, S., Zhang, S., Zhang, S.-H., Zhu, X.-L., Ni, C.-F., and, Li, Q (2021). Front. Mol. Biosci. 8:624366. doi: 10.3389/fmolb.2021.624366
In the published article, there was an error regarding the affiliations for Lei Zhang and Cai-Fang Ni. One of the affiliations was added in error. This has now been removed.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: TACE, sorafenib, HCC, platelet count, neutrophils, lymphocytes
Citation: Zhang L, Yan Z-P, Hou Z-H, Huang P, Yang M-J, Zhang S, Zhang S, Zhang S-H, Zhu X-L, Ni C-F and Li Q (2021) Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front. Mol. Biosci. 8:727969. doi: 10.3389/fmolb.2021.727969
Received: 20 June 2021; Accepted: 30 July 2021;
Published: 30 August 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Zhang, Yan, Hou, Huang, Yang, Zhang, Zhang, Zhang, Zhu, Ni and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qiang Li, rmliqiang@nbu.edu.cn
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally